JUND and breast cancer: Reduced YTHDC1 led to the destabilization of JunD proto-oncogene (JUND) mRNA in an m6A-dependent manner and impaired JUND protein levels, resulting in reduced transcription of its target gene nectin cell adhesion molecule 4 (NECTIN4), whose decreased expression ultimately reduced BC cell sensitivity to EV therapy [57].